Physician profile
Kenneth E Smith
NPI 1962409961
$9,681.18
in general payments reported to CMS, 2019-2025
50 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $487 · 2021: $1,382 · 2022: $1,320 · 2023: $1,189 · 2024: $1,857 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,641 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,641.04 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,160.03 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,137.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $853.13 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Lilly USA, LLC | $742.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $724.14 | 2019-2025 | |
| Amgen INC. | $706.63 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $621.47 | 2019-2025 | Ubrelvy, Qulipta |
| Exact Sciences Corporation | $429.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $361.81 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $281.01 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $244.85 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $225.14 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $210.90 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.12 | 2019-2025 | Xifaxan |
| Corcept Therapeutics | $166.16 | 2019-2023 | Korlym |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.